Breakthrough Combination Therapy for Weight Management
The REDEFINE 5 trial demonstrates that co-administered cagrilintide and semaglutide significantly outperforms semaglutide monotherapy for weight reduction in East Asian populations. This dual-hormone approach represents a promising advancement in obesity therapeutics, particularly relevant for Asian populations where lower BMI thresholds often predict metabolic complications. The combination leverages complementary mechanisms: semaglutide (a GLP-1 receptor agonist) reduces appetite via brain receptors and slows gastric emptying, while cagrilintide (an amylin analogue) enhances satiety signals and modulates glucose metabolism.
